Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 22;15(Suppl 1):91.
doi: 10.1186/s12978-018-0531-6.

Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India

Geetanjali Katageri  1 , Umesh Charantimath  2 , Anjali Joshi  3 , Marianne Vidler  4 , Umesh Ramadurg  5 , Sumedha Sharma  4 , Sheshidhar Bannale  6 , Beth A Payne  4 , Sangamesh Rakaraddi  7 , Chandrashekhar Karadiguddi  3 , Geetanjali Mungarwadi  3 , Avinash Kavi  3 , Diane Sawchuck  8 , Richard Derman  9 , Shivaprasad Goudar  3 , Ashalata Mallapur  1 , Mrutyunjaya Bellad  3 , Laura A Magee  10 , Rahat Qureshi  11 , Peter von Dadelszen  10 ; Community Level Interventions for Pre-eclampsia (CLIP) India Feasibility Working Group
Affiliations

Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India

Geetanjali Katageri et al. Reprod Health. .

Abstract

Background: Pre-eclampsia and eclampsia are major causes of maternal morbidity and mortality. Magnesium sulphate is accepted as the anticonvulsant of choice in these conditions and is present on the WHO essential medicines list and the Indian National List of Essential Medicines, 2015. Despite this, magnesium sulphate is not widely used in India for pre-eclampsia and eclampsia. In addition to other factors, lack of availability may be a reason for sub-optimal usage. This study was undertaken to assess the availability and use of magnesium sulphate at public and private health care facilities in two districts of North Karnataka, India.

Methods: A facility assessment survey was undertaken as part of the Community Level Interventions for Pre-eclampsia (CLIP) Feasibility Study which was undertaken prior to the CLIP Trials (NCT01911494). This study was undertaken in 12 areas of Belagavi and Bagalkote districts of North Karnataka, India and included a survey of 88 facilities. Data were collected in all facilities by interviewing the health care providers and analysed using Excel.

Results: Of the 88 facilities, 28 were public, and 60 were private. In the public facilities, magnesium sulphate was available in six out of 10 Primary Health Centres (60%), in all eight taluka (sub-district) hospitals (100%), five of eight community health centres (63%) and both district hospitals (100%). Fifty-five of 60 private facilities (92%) reported availability of magnesium sulphate. Stock outs were reported in six facilities in the preceding six months - five public and one private. Twenty-five percent weight/volume and 50% weight/volume concentration formulations were available variably across the public and private facilities. Sixty-eight facilities (77%) used the drug for severe pre-eclampsia and 12 facilities (13.6%) did not use the drug even for eclampsia. Varied dosing schedules were reported from facility to facility.

Conclusions: Poor availability of magnesium sulphate was identified in many facilities, and stock outs in some. Individual differences in usage were identified. Ensuring a reliable supply of magnesium sulphate, standard formulations and recommendations of dosage schedules and training may help improve use; and decrease morbidity and mortality due to pre-eclampsia/ eclampsia.

Trial registration: The CLIP trial was registered with ClinicalTrials.gov ( NCT01911494 ).

Keywords: Availability; Eclampsia; Health care facilities; India; Karnataka; Magnesium Sulphate; Pre-eclampsia.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by ethics review committees at the University of British Columbia, Vancouver Canada (H12-00132) and KLE University, Belgaum (Ref No: MDC/IECHSR/2013-14/A-28) India. Furthermore, approval was also obtained from the Ministry of Health and Family Welfare, India.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Say L, Chou D, Gemmill A, Tuncalp O, Moller A, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–e333. doi: 10.1016/S2214-109X(14)70227-X. - DOI - PubMed
    1. WHO Maternal Mortality Fact sheet Updated November 2016. http://www.who.int/mediacentre/factsheets/fs348/en/. Accessed 14 Jan 2018.
    1. Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN maternal mortality estimation inter-agency group. Lancet. 2016;387(10017):462–474. doi: 10.1016/S0140-6736(15)00838-7. - DOI - PMC - PubMed
    1. Duley L. Magnesium sulphate in eclampsia. Eclampsia trial collaborative group. Lancet. 1998;352(9121):67–68. doi: 10.1016/S0140-6736(05)79550-7. - DOI - PubMed
    1. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890. doi: 10.1016/S0140-6736(02)08778-0. - DOI - PubMed

MeSH terms

LinkOut - more resources